Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 2, 2010
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Goldman Sachs 31st Annual Global Healthcare Conference on June 16th in...
-
May 26, 2010Randomized study of nearly 3,000 patients to evaluate Company's third-generation drug-eluting stent technology
Boston Scientific Corporation (NYSE: BSX) today announced the initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored research...
-
May 25, 2010
Boston Scientific Corporation (NYSE: BSX) today announced CE Mark and U.S. Food and Drug Administration (FDA) approval of its NC Quantum Apex™...
-
May 24, 2010Company's iLab® Ultrasound Imaging System compatible with leading X-ray systems
Boston Scientific Corporation (NYSE: BSX) today announced collaborations with Philips Healthcare and Siemens Medical Solutions to enable the use of...
-
May 20, 2010
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events at the annual EuroPCR Scientific Program, May...
-
May 19, 2010Company expands Sterling line of peripheral angioplasty balloon catheters to include long balloons designed for below-the-knee procedures
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launches of the Sterling® SL PTA Balloon Dilatation Catheter, a...
-
May 18, 2010Next-generation system strengthens Company's endometrial ablation portfolio for the treatment of menorrhagia
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its Genesys HTA™ System for the...
-
May 13, 2010
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration clearance of the ACUITY Break-Away™ Lead Delivery...
-
May 12, 2010Approval includes specific indication for treatment of diabetic patients
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark approval for its TAXUS® Element™ Paclitaxel-Eluting Coronary...
-
May 11, 2010
Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval for LATITUDE 6.0, a software upgrade to...